Invivyd, Inc. (IVVD) Secures FDA Path for COVID-19 Antibody Approval

In this article, we will be taking a look at the 15 Best Biotech Penny Stocks to Invest in Right Now. Invivyd, Inc. stands among them.

Invivyd, Inc. (NASDAQ:IVVD) is a commercial-stage biopharmaceutical company focused on developing antibody-based therapies for serious viral infections, including COVID-19 and influenza. Its INVYMAB platform combines viral surveillance, predictive modeling, and advanced antibody engineering to deliver next-generation monoclonal antibody (mAb) solutions.

Recently, Invivyd, Inc. (NASDAQ:IVVD) announced a strategic agreement with the FDA to use a single Phase 2/3 trial as the pivotal study supporting full approval of its lead COVID-19 mAb candidate, VYD2311. This streamlined Biologics License Application (BLA) pathway positions VYD2311 as a front-runner in adaptable COVID-19 therapies, capable of addressing both prevention and emerging variants.

The firm also strengthened its financial position with a $57.5 million public offering, issuing over 89 million shares. Proceeds will fund the continued development of VYD2311 and the expansion of its infectious disease pipeline, including influenza and other viral threats. Investor confidence surged, driving the stock up more than 90%, making it one of the best penny stocks to watch in the biotech sector.

Further validating its pipeline, Invivyd, Inc. (NASDAQ:IVVD)’s VYD2311 was highlighted in the SPEAR Study Group’s recommended Long COVID antibody study design at the RECOVER-TLC Workshop, reflecting growing recognition of its potential beyond prevention.

While we acknowledge the potential of IVVD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW 

Disclosure: None.